AVTR vs XRAY Stock Comparison
Compare AVTR and XRAY across AIQ Score, fundamentals, valuation, momentum, risk, analyst expectations and current market evidence.
What is the main difference between AVTR and XRAY?
AVTR leads the current stock comparison as Avantor, Inc., with the clearest separation coming from momentum and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Avantor, Inc. vs DENTSPLY SIRONA Inc.
AVTR leads
AVTR leads by 9 AIQ points, primarily on Momentum and Risk Resilience, but the lead has narrowed from 14 points over 30 sessions. Wall Street currently favors XRAY on target upside.
Fragile: 3 of 6 evidence groups support AVTR, its lead is narrowing, and its current signal state is conflicted.
Avantor, Inc.
DENTSPLY SIRONA Inc.
The Algovestiq AIQ Score currently favors AVTR over XRAY, 56 versus 47 as of Sep 11, 2026. AVTR's advantage is driven primarily by stronger momentum and risk resilience, while XRAY holds the stronger value profile. AVTR also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors XRAY. 3 of 6 covered evidence groups favor AVTR today, and the comparison is rated Fragile on stability: only 3 of 6 covered evidence groups agree. AVTR lead: Weakening — the AIQ differential moved from 14 to 9 points over 30 sessions.
Compare Avantor, Inc. and DENTSPLY SIRONA Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price-return comparison using available daily close history.
Total return comparison
Growth of $10,000
Based on available close-price history. Distribution reinvestment is not added unless already reflected in the source series.
Compare AVTR and XRAY against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Momentum70 vs 37AVTR +33
- Risk Resilience60 vs 50AVTR +10
- Value64 vs 73XRAY +9
- Quality34 vs 27AVTR +7
3 of 6 evidence groups favor AVTR. AVTR’s edge is concentrated in momentum and risk resilience; XRAY keeps a meaningful value edge.
What changed since the last close
Latest scored session 2026-09-10, compared against the prior scored session 2026-09-09.
Largest factor move: Momentum -3
No new signals fired.
No factor moved materially.
No new signals fired.
AVTR's lead narrowed by 1 AIQ points in the latest snapshot.
Deeper signal detail for each name lives on its own signals page — AVTR and XRAY both carry a full feed there.
The central trade-off
AVTR (Avantor, Inc.): the stronger current systematic profile, led by momentum and risk resilience.
XRAY (DENTSPLY SIRONA Inc.): the counter-case, on value, fundamentals, valuation.
The AIQ Score and Wall Street therefore point in different directions on this pair.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
AVTRAVTR on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
XRAYXRAY on combined revenue and EPS growth.
Value
XRAYXRAY on the peer-relative Value factor, by 9 points.
Momentum
AVTRAVTR on the Momentum factor, by 33 points.
Lower downside
AVTRAVTR on Risk Resilience, by 10 points.
Analyst upside
XRAYXRAY on implied upside to the consensus price target.
AIQ vs Wall Street
The model and the Street disagree here: AIQ favors AVTR, analyst targets favor XRAY. That disagreement is the most useful thing on this page.
| Measure | AVTR | XRAY | Note |
|---|---|---|---|
| Implied upside to target | -28.4% | +24.3% | XRAY has more room |
| Target dispersion | +66% | +61.5% | Lower is tighter analyst agreement |
| Consensus | Hold | Hold | Context, not a primary driver |
| Analysts covering | 9 | 5 | Higher coverage generally improves confidence |
The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
3 of 6 covered evidence groups favor AVTR. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | AVTR | 56 vs 47 |
| Fundamentals | XRAYon balance | revenue growth 7% vs 2%; EPS growth -6.1% vs 4.6%; TTM ROE -10.3% vs -39.8%; gross margin 31.8% vs 49.5%; operating margin -4.4% vs 11.7% — XRAY takes 3 of 5 decided legs, not all of them |
| Valuation | XRAY | Value 64 vs 73 |
| Technicals | AVTR | Price vs 50-day 14.7% vs -13.9%; vs 200-day 42.7% vs -10.6% |
| Risk Resilience | AVTR | Risk Resilience 60 vs 50 |
| Analyst expectations | XRAY | Target upside -28.4% vs 24.3% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of AVTR and XRAY and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is moderate at 9 points.
- Only 3 of 6 covered evidence groups agree. (argues the conclusion is provisional)
- The leader's advantage has been narrowing. (argues the conclusion is provisional)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
- Analyst targets on the leader are widely dispersed. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on AVTR.
How the comparison changed
119 daily snapshots · May 4 – Sep 10AVTR lead: Weakening — the AIQ differential moved from 14 to 9 points over 30 sessions.
- Today
- AVTR +9
- 56 vs 47
- 7 sessions ago
- AVTR +9
- 58 vs 49
- 30 sessions ago
- AVTR +14
- 56 vs 42
- 90 sessions ago
- Level
- 57 vs 57
The lead changed hands once in this window, most recently on Jul 9 when AVTR moved ahead of XRAY.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
3 bullish / 1 bearish / 1 neutral, conflicted
- Golden Cross Active — bullish, trend, long horizon (23.80%)
- Bollinger Band Squeeze — neutral, volatility, short horizon
- EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
2 bullish / 0 bearish / 2 neutral
- Golden Cross Active — bullish, trend, long horizon (3.42%)
- Bollinger Band Squeeze — neutral, volatility, short horizon
- ATR Expansion - Breakout Mode — neutral, volatility, short horizon (4.53%)
AVTR leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Price and the AIQ Score both moved down over the latest session (price -0.47%, AIQ -1 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -0.38%, AIQ 0 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1XRAY closes the Momentum gap — currently 33 points behind, the largest single contributor to AVTR's edge.
- 2XRAY's Bollinger Band Squeeze turns directional — it is neutral today and would confirm a change in trend.
- 3AVTR's conflicting signal state resolves bearish — it currently carries 3 bullish and 1 bearish rules at once.
- 4The narrowing continues — the lead has already given back 5 points over 30 sessions, and a further 9-point move would eliminate AVTR's advantage entirely.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
XRAY leads on balance| Metric | AVTR | XRAY |
|---|---|---|
| Revenue growth (YoY) | 7% | 2% |
| EPS growth (YoY) | -6.1% | 4.6% |
| Gross margin | 31.8% | 49.5% |
| Operating margin | -4.4% | 11.7% |
| Return on equity (TTM) | -10.3% | -39.8% |
| Debt to equity | 0.66 | 1.71 |
Performance
AVTR leads 6 of 6 windows| Metric | AVTR | XRAY |
|---|---|---|
| 1 week (5 sessions) | 1.6% | -7% |
| 1 month (20 sessions) | 6.8% | -8% |
| 3 months (63 sessions) | 54.2% | 4.6% |
| 6 months (126 sessions) | 79.5% | -17.5% |
| Year to date | 29.8% | -8.1% |
| 1 year (252 sessions) | 13.3% | -26.1% |
Technicals
AVTR has the stronger structure| Metric | AVTR | XRAY |
|---|---|---|
| RSI (14) | 60.4 | 44.5 |
| ADX (14) | 45.9 | 20.8 |
| Price vs 50-day | 14.7% | -13.9% |
| Price vs 200-day | 42.7% | -10.6% |
| Volatility (1M, annualized) | 31.8% | 33.1% |
Risk
AVTR is the more resilient| Metric | AVTR | XRAY |
|---|---|---|
| Beta | 0.92 | 1.3 |
| Sharpe ratio | 0.48 | -0.46 |
| Sortino ratio | 0.61 | -0.73 |
| Max drawdown | -52.5% | -34.3% |
| Current drawdown | -4.6% | -28.5% |
| Annualized volatility | 51.7% | 46.4% |
| Value at risk (95%) | -4.1% | -4.2% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, AVTR or XRAY?
On the Algovestiq AIQ Score, AVTR is the stronger of the two as of Sep 11, 2026, scoring 56 against XRAY's 47. The edge comes from momentum and risk resilience. XRAY is not without a case — it holds the better value profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is AVTR or XRAY the better buy right now?
AVTR carries the stronger systematic profile as of Sep 11, 2026, and the comparison is rated Fragile — 3 of 6 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: only 3 of 6 covered evidence groups agree. Treat the lead as provisional.
Why does the AIQ Score favor AVTR over XRAY?
The composite weights Quality, Value, Momentum and Risk Resilience. AVTR leads Momentum by 33 points; AVTR leads Risk Resilience by 10 points; XRAY leads Value by 9 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, AVTR or XRAY?
Analyst price targets imply -28.4% upside for AVTR and +24.3% for XRAY, so the Street currently favors XRAY. That points the opposite way to the AIQ Score, which favors AVTR. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, AVTR or XRAY?
XRAY is the better-valued of the two on the peer-relative Value factor. XRAY on the peer-relative Value factor, by 9 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, AVTR or XRAY?
XRAY on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, AVTR or XRAY?
AVTR on the Momentum factor, by 33 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, AVTR or XRAY?
AVTR is the more resilient of the two, so the other name carries the higher downside risk. AVTR on Risk Resilience, by 10 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is AVTR more profitable than XRAY?
The profitability evidence is mixed: gross margin 31.8% vs 49.5%; operating margin -4.4% vs 11.7%; ttm roe -10.3% vs -39.8%. AVTR leads on one measure and XRAY on two measures, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.
Is AVTR's lead over XRAY getting stronger or weaker?
AVTR lead: Weakening — the AIQ differential moved from 14 to 9 points over 30 sessions. This is measured from 119 daily comparison snapshots between 2026-05-04 and 2026-09-10. The lead has changed hands once in that window, most recently on 2026-07-09, when AVTR moved ahead of XRAY.
What would change the AVTR vs XRAY verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: XRAY closes the Momentum gap — currently 33 points behind, the largest single contributor to AVTR's edge; XRAY's Bollinger Band Squeeze turns directional — it is neutral today and would confirm a change in trend; AVTR's conflicting signal state resolves bearish — it currently carries 3 bullish and 1 bearish rules at once; the narrowing continues — the lead has already given back 5 points over 30 sessions, and a further 9-point move would eliminate AVTR's advantage entirely.
What do the current signals say about AVTR and XRAY?
AVTR: 3 bullish / 1 bearish / 1 neutral, conflicted. XRAY: 2 bullish / 0 bearish / 2 neutral. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on AVTR is Golden Cross Active (bullish, long horizon). On XRAY it is Golden Cross Active (bullish, long horizon).
Compare AVTR and XRAY with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.